CLINICAL TRIALS PROFILE FOR FAMVIR
✉ Email this page to a colleague
All Clinical Trials for FAMVIR
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00098059 ↗ | Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection | Completed | Novartis Pharmaceuticals | Phase 3 | 2005-02-01 | This study will evaluate the safety and blood levels of a new pediatric formulation of Famvir in children 1-12 years of age. In Part A, patients will receive a single dose of famciclovir (12.5 mg/kg) to assess pharmacokinetics (PK) and safety. In Part B, patients will receive multiple doses of famciclovir alone or with concomitant oral anti-herpes therapy to assess safety and tolerability. Part B will start only after PK data from Part A had been analyzed. |
| NCT00306787 ↗ | Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes | Completed | Novartis Pharmaceuticals | Phase 3 | 2006-03-01 | This study will assess the safety and efficacy of one-day famciclovir (1000 mg twice a day (b.i.d)) in reducing the duration of genital herpes lesions and the associated symptoms compared to three-day treatment with valacyclovir (500 mg capsule b.i.d). |
| NCT00448227 ↗ | Pharmacokinetics, Acceptability and Safety of Famciclovir in Infants (1 Month to Less Than 12 Months) With Herpes Simplex Infection | Completed | Novartis | Phase 2 | 2007-10-01 | This study will evaluate the acceptability and safety of famciclovir in infants with herpes simplex infection |
| NCT00477334 ↗ | Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Black Patients | Completed | Novartis | Phase 4 | 2007-06-01 | This study will evaluate the safety and efficacy of single-day famciclovir episodic treatment in Black patients with recurrent genital herpes |
| NCT00834431 ↗ | Famciclovir 500 mg Tablets Under Fasting Conditions | Completed | Teva Pharmaceuticals USA | Phase 1 | 2004-08-01 | The objective of this study is to compare the relative bioavailability of famciclovir 500 mg tablets (Novopharm Limited) with that of FAMVIR® 500 mg tablets (Novartis) in healthy adult subjects under fasting conditions. |
| NCT00834444 ↗ | Famciclovir 500 mg Tablets Under Non-Fasting Conditions | Completed | Teva Pharmaceuticals USA | Phase 1 | 2004-08-01 | The objective of this study is to compare the relative bioavailability of famciclovir 500 mg tablets (Novopharm Limited) with that of FAMVIR® 500 mg tablets (Novartis) in healthy adult subjects under non-fasting conditions. |
| NCT01526408 ↗ | Famvir for Treatment of Hearing in Unilateral Meniere's Disease | Terminated | House Clinic, Inc. | Phase 3 | 2011-12-01 | The specific aim of this study is to determine the efficacy of treatment with famciclovir in unilateral Meniere's Disease patients, specifically whether hearing can be improved. The investigators will determine the percentage of unilateral Meniere's Disease patients experiencing an absence of hearing fluctuation after 3 months of treatment with famciclovir as compared to the placebo arm. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for FAMVIR
Condition Name
Clinical Trial Locations for FAMVIR
Trials by Country
Clinical Trial Progress for FAMVIR
Clinical Trial Phase
Clinical Trial Sponsors for FAMVIR
Sponsor Name
